Browsing Tag
liver disease
2 posts
How confirmatory trial pressure could shape the future of HDV treatment markets
FDA approval gave Hepcludex a major HDV breakthrough, but confirmatory trials may decide its long-term future. Read the full analysis.
Gilead Sciences completes $4.3bn acquisition of CymaBay Therapeutics to enhance liver disease portfolio
Gilead Sciences, Inc. (Nasdaq: GILD) has officially announced the successful acquisition of CymaBay Therapeutics, Inc. (Nasdaq: CBAY) for…